Zhiqiang Yang from Edgewater, NJ

Carbamate And Urea Compounds As Multikinase Inhibitors
view source
US Patent:

20210163445, Jun 3, 2021
Filed:

Dec 10, 2018
Appl. No.:

16/770697
Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US
International Classification:

C07D 401/12
C07D 215/22
C07D 487/04
C07D 487/08
C07D 403/12
Abstract:

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Macrocyclic Compounds As Trk Kinase Inhibitors And Uses Thereof
view source
US Patent:

20200385386, Dec 10, 2020
Filed:

Oct 11, 2018
Appl. No.:

16/760790
Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US
International Classification:

C07D 471/22
C07D 487/22
C07D 498/22
Abstract:

The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

Heterocyclic Compounds As Prmt5 Inhibitors
view source
US Patent:

20200369667, Nov 26, 2020
Filed:

Nov 1, 2018
Appl. No.:

16/767077
Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US
International Classification:

C07D 487/04
C07D 519/00
C07H 19/14
Abstract:

The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMTS inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMTS associated disorders are also described.

Cyclic Compounds As Immunomodulating Agents
view source
US Patent:

20200239464, Jul 30, 2020
Filed:

Sep 5, 2018
Appl. No.:

16/648213
Inventors:

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US
International Classification:

C07D 471/04
C07D 215/14
C07D 401/08
C07D 401/12
C07D 401/04
Abstract:

The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described

Fused Pyrazine Derivatives Useful As Soluble Guanylate Cyclase Stimulators
view source
US Patent:

20190307753, Oct 10, 2019
Filed:

May 11, 2017
Appl. No.:

16/301935
Inventors:

Alan WHITEHEAD - Kenilworth NJ, US
Olga ORNOSKI - Kenilworth NJ, US
Subharekha RAGHAVAN - Kenilworth NJ, US
Raphaelle BERGER - Kenilworth NJ, US
Joie GARFUNKLE - Kriens, CH
Zhiqiang YANG - Westfield NJ, US
Gang JI - Beijing, CN
Falong JIANG - Beijing, CN
Jianmin FU - Beijing, CN
- Rahway NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/519
C07D 519/00
A61P 9/12
Abstract:

The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, R, R, R, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceutical s for this purpose.

Insulin Dimer-Incretin Conjugates
view source
US Patent:

20190192675, Jun 27, 2019
Filed:

Apr 21, 2017
Appl. No.:

16/092155
Inventors:

- Rahway NJ, US
ZhiQiang YANG - Westfield NJ, US
Lin YAN - Kenilworth NJ, US
Songnian LIN - Kenilworth NJ, US
Pei HUO - Kenilworth NJ, US
Ravi NARGUND - Kenilworth NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 47/62
A61K 38/28
A61K 38/26
A61K 47/54
A61K 47/60
Abstract:

Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

Imidazo-Pyrazinyl Derivatives Useful As Soluble Guanylate Cyclase Activators
view source
US Patent:

20180193343, Jul 12, 2018
Filed:

May 23, 2016
Appl. No.:

15/575989
Inventors:

- Rahway NJ, US
Olga Ornoski - Teaneck NJ, US
Subharekha Raghavan - Bridgewater NJ, US
Libo Xu - Bridgewater NJ, US
Zhiqiang Yang - Westfield NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/519
A61P 9/12
A61P 9/04
A61P 15/10
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
Abstract:

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Preparation And Use Of 7A-Heterocycle Substituted- 6,6-Difluoro Bicyclic Himbacine Derivatives As Par-1 Receptor Antagonists
view source
US Patent:

20160200715, Jul 14, 2016
Filed:

Aug 18, 2014
Appl. No.:

14/912212
Inventors:

Zhiqiang YANG - Kenilworth NJ, US
Guizhen DONG - Rahway NJ, US
Milana MALETIC - RahWay, NJ, US
- Rahway NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07D 413/14
A61K 31/444
C07D 405/14
A61K 31/4439
A61K 45/06
Abstract:

The present invention relates to bicyclic himbacine derivatives of the formulaand the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.